Generex Biotechnology "market outperform"

01/16/08 - Rodman & Renshaw

NEW YORK, January 16 (newratings.com) - Analysts at Rodman & Renshaw reiterate their "market outperform" rating on Generex Biotechnology Corp (GNBT). The target price is set to $6.

In a research note published this morning, the analysts mention that the execution of the company’s low-risk Oral-lyn pre-commercialization activities and the preparations for the late-stage Phase III clinical trial are on track. Generex Biotechnology is a leading player in the alternative drug delivery market, the analysts add.